Summary: The tissue distribution, transfer into fetus and milk of nucleoside analogue , lamivudine, were in vestigated after a single oral administration of 3H-lamivudine to rats at a dose of 2 mg/kg . Plasma protein binding and distribution to erythrocytes of lamivudine were also examined .
Introduction
Lamivudine ((2R-cis)-4-amino-l-(2-hydroxymeth yl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one) is re ported to be a very effective agent against human and duck hepatitis B virus (HBV),1-3) and currently devel oped as an antiviral agent for human HBV by Glaxo Wellcome, UK. The absorption, metabolism and excre tion of lamivudine after a single oral administration to rats have been elucidated in the previous report. 4) In this study, tissue distribution, transfer of lamivu dine into fetus and milk were investigated after a single oral administration of tritium labeled lamivudine (3H lamivudine) to rats. Plasma protein binding and distribu tion to erythrocytes of lamivudine were also examined. Materials and Methods
Chemicals 3H-lamivudine was supplied by Glaxo Wellcome
Research and Development, UK. The structure and labeled position of 3H lamivudine is shown in Fig. 1 . The specific activity was 451 GBq/mmol and the radio chemical purity was more than 96% accounted by high performance liquid chromatographic (HPLC) analysis using an ODS column (Ultron VX-ODS, Shinwa Chemi cal Industries) and 5% (v/v) acetonitrile in 10 mM potassium dihydrogenphosphate as mobile phase. Non-labeled lamivudine was also supplied by Glaxo Wellcome Research and Development, UK. All other chemicals were of reagent grade.
Animals
Male Wistar rats at 7-8 weeks age (Charles River Japan) were used. Female Wistar rats mated at 9 weeks age (Charles River Japan) were also used on the 12th and 19th day of gestation and on the 11th day after deliv ery. The rats were fed standard laboratory diet (MF; Oriental Yeast Co. Ltd.) and water ad libitum. Environ mental conditions were always controlled at 23±3°C for temperature and 55 ± 15% for relative humidity. Except for the study on transfer of 3H-lamivudine into milk, rats were fasted overnight prior to oral dosing and for further 4 hours after dosing.
Administration
of the Drug 3H-lamivudine was dissolved in distilled water and diluted by non-labeled lamivudine. Each rat received the drug solution as a single oral dose equivalent to 2 mg/4 ml/kg body-weight. The radiolabeled doses were about 37 MBq/kg body-weight for whole body autoradio graphy (WBA) and 3.7 MBq/kg for other studies.
Tissue Distribution
<WBA> Male rats were sacrificed by ether anaesthesia at 1, 4, 24 and 48 hours after dosing. The carcass was frozen in a dry ice-hexane mixture at about -75°C. The frozen carcass was embedded in 7% sodium carboxymethyl cel lulose on a microtome stage and frozen again. Approxi mately 35µm thick sections were prepared by a micro tome (AutoCryotome; Nakagawa Seisakusyo) and freeze-dried at about -20°C. The sections were placed in contact with X-ray films (MARG 3H type; Konica). The X-ray films were exposed at 4°C for 35 days and then developed to prepare whole body autoradiograms.
<Determination of radioactivity in tissues> Male rats were sacrificed by exsanguination from ab dominal aorta under ether anaesthesia at 1, 4, 24 and 48 hours after dosing and appointed organs and tissues were collected. Plasma was separated from the blood by centrifugation. Concentrations of radioactivity in the blood, plasma, organs and tissues were determined.
Transfer into Fetus
<WBA> Female rats on the 12th and 19th day of gestation were killed by ether anaesthesia at 1, 4, 24 and 48 hours after dosing and WBAs were prepared in accordance with the above methods.
<Determination of radioactivity in tissues> Female rats on the 12th and 19th day of gestation were sacrificed by exsanguination from the abdominal aorta under ether anaesthesia at 1, 4, 24 and 48 hours af ter dosing and appointed organs and tissues were collect ed from the maternal bodies and fetus. Plasma was sepa rated from the blood by centrifugation. Concentrations of radioactivity in the blood, plasma, organs and tissues were determined. The ratios of radioactivity distributed to a fetus were also estimated.
Transfer into Milk
Milk and blood were serially collected from the lactat ing rats under light ether anaesthesia up to 72 hours af ter dosing. The milk was collected from the maternal breast or abdominal nipples after oxytocin was dosed in traperitoneally at a dose of 0.5 units/kg bodyweight. The blood was taken from the caudal vein and plasma was obtained from the blood by centrifugation. Concen trations of radioactivity in the milk and plasma were de termined.
Binding to Plasma Protein
In vitro bindings of 3H-lamivudine to plasma protein in rats, dogs and human were determined by equilibrium dialysis method. Whole blood taken from Wistar rats, beagles (Nihon Nosan Kogyo) and healthy volunteers was centrifuged to obtain plasma. 3H-lamivudine was spiked to the plasma at the range of 0.01-10µg/ml. A two-chamber type dialysis cell (Sanplatec), in which the plasma was pipetted into one-side cell of and phosphate buffer (pH 7.4) was pipetted into the other side cell, was incubated at 37°C for 22 hours. Ratio of plasma pro tein binding was calculated as follows; PB(%) = ((T-B) /T) x 100 PB : ratio of plasma protein binding (°%) T : radioactivity concentration in the cell at plasma side B : radioactivity concentration in the cell at buffer side Ex vivo binding of total radioactivity to plasma protein was determined using the same method as in vitro assay described above. Plasma was obtained from male rats af ter oral administration of 3H-lamivudine.
Distribution to Erythrocytes
In vitro distribution of 3H-lamivudine to erythrocytes was determined using whole blood obtained from rats, dogs and human. After whole blood was incubated at 37°C for 10 minutes, 3H-lamivudine was added to the blood at the range of 0.01-10 pg/ml. After further incu bation at 37°C for 30 minutes, concentrations of radioac tivity in the whole blood and plasma were determined. Ratio of distribution to erythrocytes was calculated as follows;
F(%)=[1-((Cp/Cb) x (1-H))Ix100 F : ratio of distribution to erythrocytes (%) Cp : radioactivity concentration in the plasma Cb : radioactivity concentration in the whole blood H : haematocrit value Ex vivo distribution of total radioactivity to erythro cytes was determined using the same method as in vitro assay described above. Whole blood was obtained from rats after oral administration of 3H-lamivudine.
Determination of Radioactivity
Aliquots of blood, plasma, organs, tissues and milk ob tained were combusted using a sample oxidiser (Tri carb 307; Canberra-Packard Ltd.) in order to prepare samples for determination of radioactivity. Whole fetal bodies were homogenized with distilled water and ali quots of the homogenates were combusted by the sam ple oxidiser. Radioactivity in each sample was deter mined using a liquid scintillation counter (Wallac 1410; Pharmacia) with automatic quench correction by an ex ternal standard method.
Calculation
The concentrations of radioactivity in plasma and milk were expressed as ng equivalents of lamivudine per ml. The half-lives (t112) of the radioactivity on elimina tion phase after dosing were calculated by the least square method.
The concentrations of radioactivity in or gans and tissues were expressed as ng equivalents of lamivudine per gram.
Results

Tissue Distribution <WBA>
The WBAs of 3H-lamivudine after oral administration to male rats at a dose of 2 mg/kg are shown in Fig. 2 .
Highest radioactivity was noted in the gastro-intesti nal contents at 1 hour after oral administration. The radioactivity in kidney was also obvious. Even though the overall radioactivity diminished rapidly until 4 hours post dose, high radioactivity was still noted in the intesti nal contents and urine in bladder. Low radioactivity was only noted in the urine in bladder at 24 hours post dose and radioactivity was not noted in the whole body at 48 Table I Tissue concentrations of radioactivity after single oral administration of 3H-lamivudine to male rats at a dose of 2 mg/kg <Determination of radioactivity in tissues> Mean concentrations of total radioactivity in the or gans and tissues after oral administration of 3H-lamivu dine to male rats at a dose of 2 mg/kg are shown in Table I . The concentrations of radioactivity in most of tissues showed maxima at the first sampling time of 1 hour after oral dosing and decreased rapidly with the disappear ance of radioactivity in plasma. At 1 hour post dose, the radioactivity in ileum, kidney and jejunum was higher than those in other tissues, and about 15, 9 and 4 times higher than that in plasma (450.8 ng eq./ml), respec tively. The tissue/plasma ratios of radioactivity in other tissues were below 1.7. At 4 hours post dose , the concen trations of radioactivity in ileum, kidney and jejunum decreased to 12-37Y6 of their maxima and to below de tection limit at 24 hours post dose in most of tissues .
Transfer into Fetus
<WBA> The WBAs of 3H-lamivudine after oral administration to female rats on the 12th and 19th day of gestation at a dose level of 2 mg/kg are shown in Fig. 3 and 4 , respec tively.
The radioactivity in mammary gland, placenta and ute rus was similar to that in the maternal blood at 1 hour af ter oral administration to a female rat on the 12th day of gestation. Radioactivity was scarcely noted in the fetus and amniotic fluid. Radioactivity in these tissues elimi nated rapidly and was not noted in the genital organs and fetus at 24 hours post dose.
After oral administration to female rats on the 19th day of gestation, distribution of radioactivity in the geni tal organs and fetus was similar to that in female rats on the 12th day of gestation. No radioactivity was noted in the genital organs and fetus at 48 hours post dose.
<Determination of radioactivity in tissues> Mean concentrations of total radioactivity in the or gans and tissues collected from the maternal bodies and fetus after oral administration of 3H-lamivudine to fe male rats on the 12th and 19th day of gestation at a dose of 2 mg/kg are shown in Table II and III , respectively.
After oral administration to female rats on the 12th day of gestation, the concentrations of radioactivity in uterus, ovary and placenta were 76-95% of that in the maternal plasma (540.2 ng eq./ml) at 1 hour post dose . The radioactivity in amniotic fluid and fetus were lower and about 10% of that in the maternal plasma. At 4 hours post dose, the concentrations of radioactivity in uterus, ovary and placenta decreased to 14-19°/ of their maxima. The radioactivity distributed to a fetus account ed for 0.0002% of the dose at 1 and 4 hours post dose. The concentrations of radioactivity in genital organs and fetus were below detection limit at 24 hours post dose.
After oral administration to female rats on the 19th day of gestation, concentrations of radioactivity in the uterus, ovary and placenta were 53-93% of that in the maternal plasma (691.3 ng eq./ml) at 1 hour post dose. The radioactivity in fetal whole body and all fetal tissues was less than 14% of that in the maternal plasma. The radioactivity in amniotic fluid was not detected. At 4 hours post dose, the radioactivity in uterus, ovary and placenta decreased to 34-52% of their maxima. The con centrations of radioactivity in the genital organs and fetal whole body and fetal tissues decreased to 16% or less of their maxima at 24 hours post dose and below de tection limit at 48 hours post dose. The radioactivity dis Table II Tissue concentrations of radioactivity after single oral administration of 3H-lamivudine to female rats on 12th day of gestation at a dose of 2 mg/kg Fig. 3 Whole body autoradiograms after single oral administration of 3H-lamivudine to female rats on 12th day of gesta tion at a dose of 2 mg/kg. 1; Amniotic fluid, 2; Blood, 3; Fetus, 4; Gastric contents, 5; Heart, 6; Kidney, 7; Large intestine, 8; Liver, 9; Lung, 10; Mammary gland, 11; Ovary, 12; Placenta, 13; Small intestine, 14; Uterus. tributed to a fetus accounted for 0.020%, 0.019% and 0.001% of the dose at 1, 4 and 24 hours post dose, re spectively.
Transfer into Milk
Mean concentrations of total radioactivity in the milk and plasma after oral administration of 3H-lamivudine to lactating rats at a dose of 2 mg/kg are shown in Fig.  5 . The concentrations of radioactivity in milk reached a maximum of 464.5 ng equivalents of lamivudine/ml at 4 hours post dose. The radioactivity in milk declined with a half-life of 6.5 hours up to 48 hours post dose and was below detection limit at 72 hours post dose. The concen trations of radioactivity in plasma were 160.8 ng eq./ml at 0.33 hours post dose and declined with a half-life of 7.0 hours up to 24 hours post dose. The milk/plasma ra tio of radioactivity showed a maximum of 15 at 8 hours post dose.
Binding to Plasma Protein
Mean ratios of plasma protein binding of 3H-lamivu dine in rats, dogs and human were below 7.0% at the range of 0.01-10,ug/ml in vitro (Table IV) . Mean ratios of plasma protein binding of radioactivity were below 10.7% at 1, 3 and 6 hours after oral administration of 3H-lamivudine to rats at a dose of 2 mg/kg (Table V) .
Distribution to Erythrocytes
Mean ratio of distribution to erythrocytes of 3H lamivudine in rats, dogs and human was 40.8 42.4%, 35.1-37.4% and 47.1-48.3% at the range of 0.01-10µg/ ml in vitro, respectively (Table IV) . Mean ratio of distri bution to erythrocytes of radioactivity was 44.9-51.5% at 1, 3 and 6 hours after oral administration to rats at a dose of 2 mg/kg (Table V) .
Discussion
In this study, tissue distribution, transfer into fetus and milk of radioactivity were investigated after a single oral administration of 3H-lamivudine to rats at a dose of 2 mg/kg. The previous study suggested that lamivudine was scarcely metabolized after oral administration to rats.4) Therefore the radioactivity observed in this study should reflect the disposition of unchanged drug, lamivu dine.
The concentrations of radioactivity in most of tissues showed maxima at the first sampling time of 1 hour after oral administration, indicating that lamivudine would dis tribute rapidly and extensively after oral administration. At that time, the concentration of radioactivity in kidney was higher than those in other tissues and 9 times higher than that in plasma, which may result in an extensive ex cretion of lamivudine into urine.4> The concentrations of radioactivity in cerebrum and cerebellum were much lower than that in plasma, indicating that lamivudine would little transfer to the central nervous system. The concentrations of radioactivity in other tissues, except for digestive organs, were approximate to that in plas ma, suggesting that lamivudine would distribute to most The concentrations of radioactivity in whole fetal body and each fetal tissues were less than about 14% of that in the maternal plasma at 1 hour after oral adminis tration to female rats on the 12th or 19th day of gesta tion, and the ratios of radioactivity distributed to a fetus were below 0.02% of the dose. A little lamivudine would transfer to fetus after oral administration to pregnant rats but not distribute to specific tissues of fetus. The radioactivity in whole fetal body and each fetal tissue eliminated rapidly and showed no considerable remain ing in fetus.
The concentrations of radioactivity in milk reached a maximum at 4 hours after oral administration to lactat ing rats, and were 5-15 times higher than those in plas ma from 4 to 24 hours post dose. However, the radioac tivity in milk declined with the same half-life as that in plasma, and were not detected at 72 hours post dose.
Plasma protein binding and distribution to erythro cytes of 3H-lamivudine were also examined in this study. The ratios of plasma protein binding of 3H lamivudine in rats, dogs and human were below about 7 YO at the range of 0.01-10 Mg/ml in vitro, indicating very weak binding of lamivudine to plasma protein. The ratios of distribution to erythrocytes in rats, dogs and hu man were about 35-48%, similar to haematocrit values, at the range of 0.01-10,ug/ml in vitro indicating that lamivudine would not specifically distribute to erythro cytes. The ratios of plasma protein binding and distribu tion to erythrocytes of total radioactivity after oral ad ministration of 3H-lamivudine to rats were similar to those of rats in vitro. As much total radioactivity in plas ma could be attributed unchanged lamivudine after oral administration of 3H-lamivudine to rats,4) therefore, the in vivo data may be coincident with the in vitro data.
In conclusion, it was observed in this study that lamivudine would distribute quickly and extensively in whole body after oral administration to rats and be elimi nated rapidly. A little lamivudine would transfer to fetus after oral administration to pregnant rats but it would be rapidly eliminated. Lamivudine would easily transfer to milk after oral administration to lactating rats but it would be also eliminated rapidly. The binding of lamivu dine to plasma protein would be very weak and lamivu dine would show no specific distribution to erythrocytes.
